Tranexa contraindications
Reading File
Finding Sources
Searching the Web
tranexamic acid Tranexa contraindications
Reading Web Page
tranexamic acid contraindications
Here is a comprehensive summary of Tranexamic Acid (Tranexa) contraindications:
Tranexamic Acid (TXA / Tranexa) — Contraindications
Absolute Contraindications
| Condition | Reason |
|---|---|
| Subarachnoid hemorrhage | Risk of cerebral vasospasm and ischemia |
| Active thromboembolic disease (DVT, PE, arterial thrombosis) | TXA is pro-thrombotic; worsens clotting |
| History of venous or arterial thromboembolism | Increased recurrence risk |
| Intracranial bleeding | Thrombus formation in CNS can cause ischemia |
| Known hypersensitivity/allergy to TXA | Anaphylaxis risk |
| Defective color vision (acquired or congenital) | TXA can cause ocular toxicity; baseline needed to monitor changes |
| >3 hours post-traumatic injury (in trauma indication) | No survival benefit beyond this window per CRASH-2 trial |
Additional Contraindications / High-Risk Situations
- History of DVT — a key clinical reason oral TXA is not appropriate (as noted in Rosen's Emergency Medicine in a case of heavy menstrual bleeding with prior DVT)
- Hemophilia B patients receiving prothrombin complex concentrates — combination markedly increases thromboembolism risk
- Concurrent use with Factor IX or prothrombin complex concentrates — pharmacodynamic synergism raises thrombosis risk (contraindicated per Medscape)
- Concurrent hormonal contraception — increased thromboembolic risk; non-hormonal contraception should be used during TXA therapy (FDA label warning)
Precautions (Use with Caution)
- Renal impairment — TXA is renally cleared; dose reduction required
- Coronary or vascular stent placed within the past 6–12 months — thrombosis risk
- Pregnancy — data is limited; risk-benefit must be weighed
Key Mechanism Behind These Contraindications
TXA is an antifibrinolytic — it competitively inhibits plasminogen binding to fibrin, preventing clot breakdown. This is beneficial in hemorrhage but can tip the balance toward pathological thrombosis in patients who are already prothrombotic or have active clots.
Sources: StatPearls (NCBI), FDA prescribing information, Rosen's Emergency Medicine, Medscape Drug Reference
This is a shared conversation. Sign in to Orris to start your own chat.